disulfiram has been researched along with thioguanine anhydrous in 11 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (18.18) | 29.6817 |
2010's | 4 (36.36) | 24.3611 |
2020's | 5 (45.45) | 2.80 |
Authors | Studies |
---|---|
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Ekins, S; Williams, AJ; Xu, JJ | 1 |
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Anderson, L; Bassi, ÊJ; Cardoso, SH; da Silva Santos-Júnior, PF; da Silva-Júnior, EF; de Andrade Brandão, J; Silva, LR; Xavier de Araújo-Júnior, J | 1 |
Hu, Y; Jadhav, P; Tan, B; Tan, H; Wang, J | 1 |
Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
Chen, WY; Cheng, SC; Chu, HF; Kuan, Y; Lin, HC; Lin, TH; Pan, HC; Sun, CY | 1 |
An, X; Chu, M; Dai, X; Li, Q; Li, Z; Yu, H; Zhang, D | 1 |
3 review(s) available for disulfiram and thioguanine anhydrous
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Druggable targets from coronaviruses for designing new antiviral drugs.
Topics: Animals; Antiviral Agents; Drug Design; Humans; Middle East Respiratory Syndrome Coronavirus; Pandemics; SARS-CoV-2 | 2020 |
Progress and Challenges in Targeting the SARS-CoV-2 Papain-like Protease.
Topics: Antiviral Agents; Coronavirus Papain-Like Proteases; COVID-19 Drug Treatment; Humans; Pandemics; Protease Inhibitors; SARS-CoV-2 | 2022 |
8 other study(ies) available for disulfiram and thioguanine anhydrous
Article | Year |
---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Disulfiram and 6-Thioguanine synergistically inhibit the enzymatic activities of USP2 and USP21.
Topics: Disulfiram; Drug Synergism; Enzyme Inhibitors; Humans; Thioguanine; Ubiquitin Thiolesterase | 2021 |
Combination of the 6-thioguanine and disulfiram/Cu synergistically inhibits proliferation of triple-negative breast cancer cells by enhancing DNA damage and disrupting DNA damage checkpoint.
Topics: Acetaldehyde Dehydrogenase Inhibitors; Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Cycle Checkpoints; Cell Proliferation; Copper; Disulfiram; DNA Damage; Drug Therapy, Combination; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; NF-kappa B; Phosphorylation; Thioguanine; Triple Negative Breast Neoplasms; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2022 |